Kornimate/medical-research-clean huggingface dataset:
effects of sleep deprivation on cerebrospinal fluid (csf) amyloid-beta (aβ) dynamics

Conditions: Alzheimer Disease

Summary: introduction: alzheimer's disease (ad) is characterized by neurodegeneration of the brain in the form of neurofibrillary tangles and plaques containing the amyloid-beta protein (abeta). recent animal studies have shown that extended wakefulness is associated with increased production of these abeta proteins and that sleep leads to a marked fall in their production. aim: the investigators aim to distinguish a similar effect of sleep disturbance on cerebrospinal fluid (csf) abeta levels in humans, which may point out sleep disturbance as an important factor in ad development. methods: a study in 26 healthy male volunteers, measuring csf abeta levels during a sleep deprivation night and before and after a control night with unrestricted sleep. expected results: the investigators expect sleep deprivation to lead to an increase in csf abeta levels, as compared to the levels in the control night.


Eligibility criteria:
inclusion criteria: * written informed consent * age 40-60 years * male * subject is in good health as established by medical history, physical examination, ecg and laboratory examination * laboratory parameters (as described on in section 3.7 screening) should be within the normal ranges as applicable in runmc, nijmegen, or clinically acceptable to the investigator * normal sleep behaviour, pittsburg sleep quality index score ≤5 * mmse 28 or higher * medication free exclusion criteria: * presence of blood coagulopathy, established by medical history * allergy to local anesthetic agents * contra-indication for spinal catheter placement: medical history of compression of spinal cord, spinal surgery, skin infection, developmental abnormalities in lower spine * subjects who are currently participating in another study or have participated in a clinical study within 30 days, based on their own report about participation history * subjects with a history of drug or alcohol abuse * subjects who are part of the study staff personnel or family members of the study staff personnel

Keywords: alzheimer disease cerebrospinal fluid sleep abeta
cardiometabolic risk of shiftwork

Conditions: Sleep Deprivation; Circadian Dysregulation; Shift-Work Sleep Disorder

Summary: the overall goal of the present application is to test the hypothesis that shift workers, who are chronically exposed to circadian misalignment and sleep loss, have a higher cardio-metabolic risk than day workers, and that the accumulated sleep debt and the degree of circadian misalignment both predict their elevated cardio-metabolic risk.


Eligibility criteria:
inclusion criteria: * day workers and shift workers at the university of chicago, university of chicago medical center, or another chicago area medical center who have maintained their work schedule (at least 30 hours/week) for at least 6 months. * individuals who have been shift workers for less than 10 years; body mass index \<40 kg/m2; * no major illness * no history of psychiatric, endocrine, cardiac or sleep disorders * those with hypertension or dyslipidemia will be included if these conditions are controlled by a stable treatment. * women taking oral contraceptive or hormonal replacement therapy will be included only if they plan to stay on a stable regimen throughout the study. * age must be between 18 and 50 years exclusion criteria: * individuals who have worked at the university of chicago, university of chicago medical center, or another chicago area medical center in their current position for less than 6 months. * individuals who have been shift workers for more than 10 years * bmi\>40 kg/m2 * individuals with a major illness (e.g. diabetes, sleep disorder)
study to compare self-administered and nurse-administered intradermal influenza vaccine

Conditions: Influenza

Summary: the purpose of this study is to compare the immunogenicity and reactogenicity of self-administered intradermal influenza vaccine (intanza)to nurse-administered.

participants will be randomized at visit one to either receive self-administered or nurse-administered intradermal influenza vaccine (intanza). a blood sample will be taken prior to vaccination and 21 days post-vaccination. participants will record information in a memory aid for 7 days including daily temperatures, solicited, unsolicited and general reactions. they will be called on study day 8 to collect this information. participants will return 21-24 days later for follow-up serology and review of adverse events.

Eligibility criteria:
inclusion criteria: * medically stable persons between age of 18-60 * available during the trial period and for follow-up * able to read, understand, and sign informed consent * able to be contacted by telephone for follow-up of adverse events exclusion criteria: * use of experimental vaccines within the month prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products during the duration of the study. * receipt of immunoglobulin or other blood product within 3 months prior to enrollment * receipt of other licensed vaccines within the preceding 4 weeks * history of a severe reaction following influenza vaccination * use of cytotoxic therapy or biologic modifiers in the previous 2 years. * plans to receive cytotoxic therapy during the study period. * concurrent acute moderate to severe illness. (vaccination will be deferred until recovery. subjects with mild illnesses with fever ≤37.8ºc orally may be enrolled). * history of medical disorder associated with immunosuppression (eg. including hiv-infected individuals, transplant recipients) * history of chronic lung, cardiac, renal or liver disease, which has required hospitalization in the last year. * receipt of any high-dose daily systemic corticosteroids (inhaled steroids are acceptable) within two weeks of study entry. high dose is defined as a dose of 20 mg of prednisone daily or its equivalent. topical steroids are allowed. * failure to give written, informed consent * history of febrile illness (\>37.8ºc orally) within the past 72 hours (immunization may be deferred). * known allergy to eggs or other components of vaccine (i.e., thimerosal) * history of guillain-barré syndrome (gbs)
clinical feasibility of mobile app-based self-management for breast cancer-related lymphedema

Conditions: Breast Cancer Related Lymphedema

Summary: the study evaluates a newly developed service that provides personalized self-management guidance based on evidence-based arm circumference measurements and resulting volume changes. the research aims to determine whether this digital solution is practical and acceptable for patients while identifying any unexpected challenges during implementation, ultimately establishing its potential for clinical integration into lymphedema care.


Eligibility criteria:
inclusion criteria: * between 18 and 70 years of age * diagnosed with breast cancer-related unilateral upper limb lymphedema * possessing an android or ios smartphone * voluntarily deciding to participate and providing written consent after receiving a detailed explanation of this study exclusion criteria: * diagnosed with malignant lymphedema due to metastasis or recurrence * having severe comorbidities (underlying diseases, neuromusculoskeletal disorders, cognitive, mental, or visual impairments, etc.) that make it difficult to use the application and participate in exercise interventions discontinuation criteria: * development of serious complications or cancer metastasis/recurrence during the study period * occurrence of a serious illness unrelated to study participation * failure to follow the instructions of the study physician * voluntary withdrawal from the study or development of circumstances preventing participation
a study of brl49653c for the treatment of type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study is designed to evaluate the safety of brl49653c administrated for 52 weeks


Eligibility criteria:
inclusion criteria: - patients with type 2 diabetes mellitus managed by diet therapy or one antidiabetic agent (sulfonylurea or alpha glucosidase inhibitor) will be candidates for this study. these candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function. exclusion criteria: - patient with serious cardiovascular disease or serious hepatic disease will not be eligible.

Keywords: type 2 diabetes mellitus; diabetes; rosiglitazone avandia;
transcriptomic signature of vasospasm consecutive to sub-arachnoid aneurismal hemorrhage

Conditions: Aneurysmal Subarachnoid Hemorrhage; Vasospasm

Summary: rational: the main danger with intracranial aneurism is its rupture conjugated with subarachnoid hemorrhage (sah) occurrence. sah is a severe pathology leading not only to neurological but also extra cerebral disorders. the major cause of morbidity and mortality when developing a sah is the secondary development of a delayed cerebral ischemia consecutive to a prolonged vasospasm of cerebral arteries. the understanding of the pathophysiological mechanisms of sah complication, such as vasospasm which is the more frequent, is essential. vasospasm is defined as a reversible shrinking of an artery lumen diameter in the subarachnoid space, beginning generally between 4 and 12 days after the hemorrhage. such a vasospasm could have a huge clinical impact leading to delayed neurological ischemic deficiency in 17 to 40 % of cases. up to day, mechanisms involved in vasospasm occurrence are not well described. disposing of well-established genetics and transcriptomics databases along with cerebral ischemia and inflammation is essential to unravel the mechanisms leading to vasospasm occurrence on sah patients. it will enable researchers to better comprehend sah pathology and elaborate an efficient and individualized therapeutic strategy to sah acute phase in order to reduce the risk of vasospasm occurrence. aims: 1) constitute dna and rna biobank via blood proofing oh sah patients 2) constitute a database grouping clinical and biological data 3) look for genetic and transcriptomic early markers via genomic approaches 4) correlate these different markers with vasospasm occurrence and clinical evolution of the patients study: patients inclusion will be done following their admission (d1) in the " unité de réanimation neurochirurgicale" of pitié-salpètrière hospital. after obtaining of the informed consent, blood proofing will be realized daily during 12 days: one daily 2.5ml tube for the transcriptomic study and a single 10ml edta tube for genetic analyses. clinical and biological follow-up will be performed as usual. 200 patients will be initially included during 2 to 3 years for the transcriptomic study of which 1/3 will develop vasospastic complication. the transcriptomic study will thus be performed by comparing patients developing or not developing this complication expected results: unravel vasospasm early genetic markers.


Eligibility criteria:
inclusion criteria: * patient entering the neurosurgical unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) * aged more than 18 * caucasian origin * affiliated to a social care service * having (or one of is related if he is comatose) given its informed consent exclusion criteria: * subjects which do not have a social care protection * subjects (or one of is related if he is comatose) refusing to sign the consent * subjects being under a protective juridical system for adults

Keywords: aneurysmal subarachnoid hemorrhage vasospasm transcriptomic case-control study
once versus twice bisoprolol dosage regimen in prevention of atrial fibrillation post coronary artery bypass graft surgery

Conditions: Coronary Artery Bypass Grafting; Postoperative Atrial Fibrillation; Coronary Artery Disease

Summary: the goal of this interventional clinical trial is compare between two different dose regimens of bisoprolol (beta-blocker) in cabg patients in terms of efficacy and safety.


Eligibility criteria:
inclusion criteria: * adult patients: 18 to 65 years old * diagnosed with coronary heart disease or myocardial infarction and scheduled for coronary artery bypass surgery exclusion criteria: * history of ventricular arrhythmia, atrial fibrillation, atrial flutter, left bundle block, av block grade ii/iii * history of sick sinus syndrome, sinoatrial heart block * history of valve replacement * permanent pacemaker * lvef less than 30% * unstable heart failure * cardiogenic shock * sustained systolic blood pressure less than 100 mmhg or hr less than 50 bpm at recruitment * severe chronic obstructive airway disease * severe asthma unless was on previously tolerated bisoprolol dose * uncontrolled diabetes mellitus unless was on previously tolerated bisoprolol dose * pregnant/lactation * previous recent stroke * creatinine clearance less than 30 ml/min * end stage liver disease (liver cirrhosis) * drug dependance history * untreated phaeochromocytoma * vasospastic angina * thyrotoxicosis * history of advanced staged of peripheral vascular disease * hypersensitivity * patients on any other beta-blocker other than bisoprolol * patients on bisoprolol higher than 5 mg/day.

Keywords: bisoprolol dosage regimens heart rate blood pressure
impact of travel neck pillow use on neck comfort and mobility after thyroidectomy

Conditions: Total Thyroidectomy

Summary: this study aims to evaluate the effectiveness of u-shaped travel neck pillow use in improving cervical comfort, reducing neck pain and stiffness, and enhancing cervical range of motion in adults undergoing total thyroidectomy surgery. it is the first randomized controlled trial in turkey to examine the use of a travel neck pillow as a non-pharmacological intervention during the immediate postoperative period (day 0). the study will be conducted at erciyes university gevher nesibe hospital between december 5, 2024 and june 5, 2025. participants will be randomly assigned to either the pillow group or the control group. those in the pillow group will use a u-shaped neck pillow for the first 24 hours after surgery while at rest. outcomes will be assessed using the visual analog scale (vas) for pain and comfort, the mcgill pain questionnaire for pain localization and intensity, and goniometric measurements of cervical range of motion. data will be collected preoperatively and at 24 hours postoperatively. this study is expected to provide clinical evidence supporting the use of travel neck pillows to improve postoperative comfort and mobility, offering a simple and cost-effective nursing intervention for thyroidectomy recovery.


Eligibility criteria:
inclusion criteria: * scheduled to undergo elective total thyroidectomy classified as asa physical status i or ii aged 18 years or older no communication impairments willing to participate and provide informed consent exclusion criteria: * patients with a previously diagnosed condition in the cervical spine region prior to surgery patients who have previously undergone thyroidectomy

Keywords: cervical comfort postoperative neck pain neck stiffness u-shaped travel neck pillow cervical mobility nursing care
prevalence of chronic kidney disease and its association with clinical outcome in patients with coronary heart disease

Conditions: Coronary Heart Disease; Chronic Kidney Disease

Summary: this is a prospective, multi-center, hospital-based observational study. the aim of the study is to evaluate the prevalence of chronic kidney disease in patients with stable coronar heart disease.

the primary aim of the study is to evaluate the prevalence of chronic kidney disease(ckd) in patients with stable coronary heart disease. the secondary aims include: 1. to evaluate the awareness of ckd in patients with stable coronary heart disease. 2. to find out risk factors that is associated with ckd in these patients. 3. to evaluate the association between ckd and cardiovascular events during one-year's follow-up. based on sample size estimation, the plan is to recruit 10000 patients from 100 centers. patients who participate the study will finish one-year's follow up (0 day, 6 months and 12 months after recruitment). during the baseline visit, patients' demographic characters will be collected, and laboratory tests will be performed for urinalysis, renal function, hepatic function, etc. during the 6 months' follow up, mace(major adverse cardiovascular events) will be recorded through phone or face to face interview between investigators and patients. mace include all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, documented re-hospitalization for unstable angina pectoris, and coronary revascularization (including percutaneous coronary intervention and cabg). during the 12 month's follow up, mace will be recorded, and laboratory tests will be performed again.

Eligibility criteria:
inclusion criteria: * age≥18 years. * patients with clinical evidence of stable coronary heart disease, who meet at least one of the following three criterias: a. stable coronary heart disease with objective evidence of atherosclerosis, either coronary angiography shows ≥50% stenosis of at least one of the coronary main stems or first-level branches, or typical exertional angina pectoris with positive stress tests(ecg stress test, echocardiograph stress test, or stress radionuclide myocardial imaging). b diagnosed of myocardial infarction at least 3 months before recruitment. c.coronary revascularization(pci or cabg) at least 3 months before recruitment. * informed consent signed by patients or legal guardians. * willing to and capable of being followed up for 1 year. exclusion criteria: * non-atherosclerotic coronary heart disease * deterioration of heart failure during the past 3 months * exposed to contrast agent during the past one month. * history of amputation * pregnancy * female patients in menstrual period(still eligible after menstrual period) * organ failure other than heart failure and kidney failure * comorbid other diseases, and life expectancy \<1 year * considered not fit for the study due to other reasons, including but not restricted to : a. severe infection; b. acute kidney injury.

Keywords: chronic kidney disease stable coronary heart disease prevalence
effect of alternate day fasting over standard medical management alone to reverse non-alcoholic steatohepatitis.

Conditions: Non Alcoholic Steatohepatitis

Summary: the aims of this study are as follows: to compare the role of alternate-day fasting over standard medical management alone to reverse nash.

emerging evidence suggests the role of alternate-day fasting (adf) in patients with obesity and fatty liver. it helps to lose weight and improvement in liver fat content. adf regimen protocol includes fast day(restricted calorie intake and time-specific feeding) and feast day(ad libitum feed over 24 hours). lowering the weight and improvement of the fatty liver. nash is a prevalent cause of liver disease. literature is evident that adf improves fatty liver and metabolic components, and nash improves with weight loss. still, data about the role of adf in the management of nash is lacking. hence, this study focuses on the role of adf in nash.

Eligibility criteria:
inclusion criteria: * age 18-65 years. bmi 25-40kg/m3, and cap more than 290 * stable weight in the last 3 months prior to enrolling in the study(\<5kg weight variation) * imaging showed steatotic liver disease, liver stiffness \<14kpa measured by fibroscan * histologically proven nash/mash, fibrosis up to f3 * subjects willing to participate in the study exclusion criter * liver stiffness \>14kpa measured by fibroscan or fibrosis \>f3 * diabetes with hba1c\>8.5% * patients with another co-existing active liver disease e.g. hepatitis b or c, alcoholic liver disease * patients with cirrhosis, hepatocellular carcinoma(hcc), or other malignancy * chronic kidney disease, cardiovascular disorders, uncontrolled hypertension * chronic infections, chronic inflammatory diseases * patients on weight loss medications e.g semaglutide * pregnant or lactating women and those planning a pregnancy a patient who is not willing to participate in the study or failed to provide the consent

Keywords: alternate day fasting. nash mash steatotic liver disease cirrhosis
spa rehabilitation after cruciate ligament injury in sportsmen

Conditions: Cruciate Ligament Injury; Balance Control

Summary: knee cruciate ligament injury is a common injury (15 000 per year in france) which concerns young sportsmen. consequences are limitation in physical and sporting activities and at work. main objective: to compare water and traditional rehabilitation after cruciate ligament injury reconstruction in terms of kinematics of recovery and of proprioceptive abilities development.

secondary objectives: to compare algo-functional and sport, social and job come back date between both groups. multicentric randomised trial comparing two therapy protocols in knee cruciate ligament injury. after surgery, 2 weeks rehabilitation; 3 weeks conventional rehabilitation (group 1) or rehabilitation in water (group 2). data will be collected at inclusion (before surgery), 2 weeks, 1 month, 2 months and 6 months after surgery.

Eligibility criteria:
inclusion criteria: * adults, * 18-49 years, * indication of knee anterior cruciate ligament reconstruction. exclusion criteria: * other recent lower limb sprain, * history of neurological disease (stroke, central or peripheral degenerative disease), * psychtrope or antihypertensive drugs, * aquatic activities contra-indication (cutaneous).

Keywords: cruciate ligament injury balance control rehabilitation spa therapy sport
rotem versus aptt/pt in pediatric surgery

Conditions: Coagulation Defect; Bleeding

Summary: hemocoagulation management in perioperative bleeding is nowadays based on standard coagulation testing: activated partial thromboplastin time (aptt), prothrombin time (pt), fibrinogen, d-dimers, platelets. an interest about viscoelastic coagulation testing methods is rising - use of rotational thromboelastometry (rotem) is mentioned in the newest european guidelines for hemostasis management. rotem has more advantages then standard tests. however, both tests have only grade 1c recommendation, and most of trials have been done on adults. the goal of the study is to compare a relationship between standard tests and rotem in pediatric patients in perioperative period to find out which test has better correlation with clinical status, to compare therapeutic strategies and time necessary for gain both of tests and to compare the difference in blood loss and blood products consumption in group treated by rotem versus standard tests. reduced blood loss and amount of blood products transfusion is expected to be found in rotem group, representing lowering risk for the patient, all due to early evaluation of hemocoagulation and targeted therapy guided by rotem.

pediatric patients who underwent spine surgery (under 18 years old) will be recruited in our study. retrospective data will be analysed from these patient who underwent scoliosis surgery before rotem implementation to daily practice and after rotem implementation do daily practice in our department. time to available results of rotem versus aptt/pt tests will be compared. blood loss and blood products used in these both groups will be analysed and compared between 2 groups.

Eligibility criteria:
inclusion criteria: • pediatric patients after surgical correction of scoliosis exclusion criteria: • patients older than 18 years

Keywords: rotem, pt, aptt